Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Total Debt (2022 - 2025)

Historic Total Debt for Rxo (RXO) over the last 4 years, with Q4 2025 value amounting to $404.0 million.

  • Rxo's Total Debt rose 978.26% to $404.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $404.0 million, marking a year-over-year increase of 978.26%. This contributed to the annual value of $404.0 million for FY2025, which is 978.26% up from last year.
  • Rxo's Total Debt amounted to $404.0 million in Q4 2025, which was up 978.26% from $403.0 million recorded in Q3 2025.
  • In the past 5 years, Rxo's Total Debt registered a high of $455.0 million during Q4 2022, and its lowest value of $11.0 million during Q3 2022.
  • For the 4-year period, Rxo's Total Debt averaged around $377.9 million, with its median value being $403.0 million (2025).
  • The largest annual percentage gain for Rxo's Total Debt in the last 5 years was 402727.27% (2023), contrasted with its biggest fall of 2109.89% (2023).
  • Quarter analysis of 4 years shows Rxo's Total Debt stood at $455.0 million in 2022, then decreased by 21.1% to $359.0 million in 2023, then rose by 2.51% to $368.0 million in 2024, then increased by 9.78% to $404.0 million in 2025.
  • Its Total Debt was $404.0 million in Q4 2025, compared to $403.0 million in Q3 2025 and $403.0 million in Q2 2025.